23 Reasons to Choose SelfDecode

Almost every consumer genetics company claims to be the best. The claim has become so universal it stopped meaning anything. So here is the honest version. The right way to choose a genetics company is to apply a concrete framework and see which company survives it: advanced peer-reviewed science, real sequencing quality, report breadth, ancestry-aware risk prediction, multi-omics integration of your DNA, labs, and lifestyle, privacy posture, editorial rigor, and the actual customer experience. This page is that framework, applied.

Each reason below leads with what it means for you, and every reason is backed by verifiable facts you can check against published papers, the platform itself, or the public record. And on every claim we tell you not just what we do, but what other companies do, because the only way to judge a genetics company is by comparison.

The single most important thing to understand before you compare: this is an industry built on confident half-truths. When a company cannot show you an advanced, validated, published polygenic risk score or a genuinely clinical-grade whole genome pipeline, its reports are not “unverified but probably fine.” They are inaccurate. They give confidently-stated wrong answers that push people toward the wrong health decisions. “Not validated” is the polite phrase. The accurate phrase would be: incorrect/random. SelfDecode is built so that does not happen to you.

This is a living page. New reports, validation work, partnerships, and features are added throughout the year.

A. Accuracy: why we are confident in our data

1. SelfDecode is the only consumer genetics company whose advanced polygenic risk scores are validated and published in a peer-reviewed Nature journal.

Most DNA companies sell “risk scores” that have never been validated by anyone. That does not make them unverified. It makes them wrong for most people. SelfDecode’s advanced scoring is the rare exception that has been published, peer-reviewed, and held up.

• a. SelfDecode’s PRS methodology is published in Scientific Reports (May 2025), a peer-reviewed Nature journal: Optimization of multi-ancestry polygenic risk score disease prediction models (Lerga-Jaso et al., 2025;15:17495).
• b. A second paper appeared the same month in Nature Communications, also a Nature journal: Tracing human genetic histories and natural selection with precise local ancestry inference (May 16, 2025), introducing the Orchestra ancestry model.
• c. The methodology combines an ensemble of five PRS algorithms trained on a trans-ancestry GWAS meta-analysis (UK Biobank, FinnGen, BioBank Japan, Million Veteran Program, and others), which boosts case sample sizes about 6.4 times over UK Biobank alone. This is the engine. What it gives you is a score that is actually right for your biology.
• d. Contrast: a PubMed search for the major brand-name competitors plus “polygenic risk score” or “validation” returns zero results. If a company points to 23andMe and says it does risk scores, those are basic single-variant or array-based scores, not advanced, validated, published PRS. As far as we could find, no consumer genetics company has ever published a peer-reviewed PRS validation paper. An unpublished, unbenchmarked, ancestry-uncalibrated score does not produce a noisier version of the right answer. It produces a confidently wrong one.
• Evidence: PRS paper and Orchestra paper

2. Your risk scores are validated across 150 medically-related conditions and benchmarked to beat the best models in the field.

It is not enough for a score to be “published.” It has to outperform the leading reference models on independent populations. SelfDecode’s does. And it has to use real prediction science, not single-variant guesswork.

• a. SelfDecode’s PRS validation spans 150 medically-related conditions. The published paper details 30 of them (including coronary artery disease, breast cancer, type 2 diabetes, atrial fibrillation, prostate cancer, Alzheimer’s, Parkinson’s, Crohn’s, ulcerative colitis, schizophrenia, melanoma, ischemic stroke, rheumatoid arthritis, and systemic lupus erythematosus), and a new paper is set to be submitted that validates the full 150 as accurate and the gold-standard.
• b. Models were validated on the eMERGE Network and the PAGE Multiethnic Cohort, two of the most respected independent multi-ancestry validation cohorts, both containing populations not used in training.
• c. The SelfDecode ensemble outperformed the UK Biobank PRS Release (Thompson et al., 2024) for 26 of 30 traits (median AUC +5.07%) and beat the eMERGE clinical PRS implementation for 6 of 8 overlapping traits. 12 of 30 models exceed 80% AUC with clinical factors, and 19 traits exceed a diagnostic odds ratio of 10 across all ancestry groups. This is the most advanced polygenic risk scoring on the market.
• d. The coronary artery disease PRS identifies 55 to 80 times more true coronary events than rare pathogenic-variant models, because it captures the large pool of people whose risk comes from common variants, not the rare mutations that get all the attention.
• e. Why this matters and what “scientific” really means: many companies say their reports are “backed by science” and point to PubMed. Look closely and it is usually a single-variant association study (one RSID linked to one trait or a GWAS). The effect size of any single common variant is so small in these studies that it is clinically irrelevant, and no bioinformatician treats single variants as a basis for predicting a trait or condition (pharmacogenomics is the narrow exception). Real prediction requires advanced, validated polygenic risk scoring. That is the difference between citing science and doing science.
• f. Contrast: competitors cannot benchmark because their methodology is not public. There is nothing to check, nothing to compare, and no result anyone can trust.

3. Accuracy that holds across ancestries, not Europeans only.

Most genetic risk scores were built almost entirely on European data and quietly break down for everyone else. If you are Black, Hispanic, East Asian, South Asian, or of mixed ancestry, the risk numbers most companies hand you are not just less precise, they are frequently wrong. SelfDecode is built to work regardless of your background, and is one of the very few platforms whose published validation reports accuracy separately for non-European groups.

• a. The Orchestra local-ancestry model resolves ancestry at far higher granularity than the continental-level estimates other platforms use, so your variants are interpreted in your ancestral context.
• b. The training meta-analysis was specifically designed to improve performance in non-European populations, and validation reports performance separately for each group (Black or African, Asian, White, Latino, Native American, Hawaiian, Japanese).
• c. Whole genome sequencing reads every position regardless of ancestry. Unlike genotyping arrays designed against European reference panels, the technology itself carries no ancestry bias.
• d. Contrast: SelfDecode openly states the field-wide European versus non-European gap has been narrowed, not closed. Almost no competitor discusses the gap at all, and an array-based score reported as a clean percentile is, for most non-European users, simply wrong.

B. Sequencing quality: the raw material everything is built on

4. SelfDecode runs a genuinely clinical-grade whole genome pipeline, which almost no consumer company does.

Bad genomic data can be worse than no data. Whenever it provides wrong answers, it can lead one to take potentially harmful actions. The file looks identical to a real one, but the errors are hidden where you will never see them. SelfDecode’s pipeline is built to clinical standards end to end.

• a. 30x whole genome sequencing with paired-end Illumina reads, reading all 3.2 billion base pairs. That is not just the few hundred thousand positions an array reads, nor the 1 to 2% an exome covers.
• b. Variant calling uses DRAGEN, the same caller used by clinical labs worldwide and benchmarked against the PrecisionFDA Truth Challenges. Alignment is against the current GRCh38 reference (not the outdated GRCh37 some providers still use), with quality filtering calibrated against Genome in a Bottle truth sets across ancestral backgrounds.
• c. Sensitivity and specificity are measured against reference genomes, not asserted. We run our own quality control and reject files that do not pass it.
• d. Contrast: when another company advertises “30x,” it is usually maximum 30x, not real 30x. In practice you may be getting 10x, which is not enough to call rare variants properly, and most consumer companies do not use DRAGEN because it is expensive. Even a file that says “30x” is usually not clinical grade and cannot be used for real decisions. (See Reason 6 for the full picture of how sequencing quality stacks up.)

5. SelfDecode reads parts of your genome other tests miss entirely.

The hardest regions of the genome are also some of the most medically important, and most consumer tests skip them.

• a. Structural variants are detected reliably, including the deletions, duplications, inversions, and CNVs behind conditions like spinal muscular atrophy (SMN1) and 22q11 deletion syndrome.
• b. Mitochondrial DNA is analyzed alongside the nuclear genome.
• c. HLA typing (the most clinically consequential and hardest-to-type region) and CYP2D6 typing are done at the resolution real pharmacogenomic prescribing requires. HLA is full-resolution immune-system typing, linked to autoimmune risk, drug hypersensitivity, and transplant compatibility. CYP2D6 has structural variants, duplications, and a pseudogene that make it notoriously hard to type.
• d. For uploaded genotype data, imputation expands a 750,000-SNP file to 200M+ variants at about 99.7% accuracy, so 23andMe and AncestryDNA customers get validated PRS without re-sequencing.
• e. Contrast: mitochondrial DNA, accurate HLA, and CYP2D6-grade pharmacogenomics are absent in consumer products. We do not know a single consumer company that offers them.

6. There are six levels of genetic sequencing, and almost every other company sits near the bottom.

One key reason to choose SelfDecode is the kind of genetic data you actually get, because the levels are far from equal. Keep in mind this is only related to the sequencing/genotyping. It’s not related to the actual analysis, which is often worse. Just for sequencing, this is what’s out there.

• a. Level 1, the worst: 1 to 1,000 variants. Most consumer and functional medicine companies look at somewhere between one and a thousand genetic variants and build their whole pitch on it. A handful of variants cannot predict traits or conditions. This is the bottom of the market.
• b. Level 2: genotyping arrays without good imputation. These read the 700,000 to roughly 1 million positions on the chip and nothing more, so you only ever see the variants the array happened to test.
• c. Level 3: whole exome (for example, CircleDNA). Better than an array in some ways, but it misses too much. You cannot do good polygenic risk scores, you cannot do full pharmacogenomics, and you cannot reliably call rare variants.
• d. Level 4: poor-quality whole genome sequencing (for example, Dante Labs). Companies advertise whole genome, but the level of depth matters significantly. If it is less than 30x (1x-29x) you are not able to accurately call rare variations. What you often get is around 10x or less with weak bioinformatics, which results in an inability to call rare variants.
• e. Level 5, advertised 30x whole genome. Here the sequencing is marketed as true 30x, even by legitimate labs, but check the underlying data and it often is not actually 30x, so it still misses the rare variants real 30x is meant to catch.
• f. Level 6, where SelfDecode operates: genuinely clinical-grade whole genome at a true minimum 30x, with real bioinformatics and quality control that rejects bad files. Almost all consumer companies are not doing this properly, which means you are largely wasting money, because “maximum 30x” delivered at 10x cannot surface the rare variants and the depth that whole genome is supposed to provide.
• g. Sequencing is only half of it. We also use the whole genome. It is one thing to sequence a whole genome, another to actually analyze all of it. Even the rare competitor that sequences well tends to read only narrow regions: essentially ACMG findings plus basic carrier screening plus weak PRS, with no real recommendations, leaving the overwhelming majority of your genome not analyzed. SelfDecode analyzes across your entire genome and turns it into the most comprehensive output in the industry:

•  the most comprehensive pharmacogenomics and carrier status reports available,

•  nutrigenomics, pathway analysis, and HLA typing,

•  mitochondrial variants, high-risk (pathogenic) variants, and rare-variant analysis beyond the ACMG list,

•  and 1,500+ polygenic risk scores spanning your whole genome.

And because it is your file, SelfDecode reanalyzes the same genome forever as the science advances, so your cost per insight approaches zero over time.

• h. How we know: we spent over a year and a half evaluating labs worldwide. Many promised 30x and did not deliver; we ran our own QC, sent files back, and required re-sequencing. Companies selling whole genome for around $300 are not doing it properly, full stop.

C. Breadth and depth of what you actually get

7. 1,500+ reports from a single sample, more than any company we have found.

One swab, sequenced once, becomes a library no competitor’s report count comes close to.

• a. 1,500+ health, trait, and condition reports come from the same genome, with no re-sequencing required to access any of them. They are the most comprehensive set by type in the industry, including the most comprehensive pharmacogenomics and carrier status reports available, plus nutrigenomics, pathway analysis, HLA, mitochondrial variants, high-risk variants, and rare-variant analysis beyond the ACMG list, all from the same genome (detailed in the reasons below).
• b. All 81 genes on the ACMG SF v3.2 actionable-findings list are covered (BRCA1, BRCA2, Lynch syndrome, familial hypercholesterolemia, hypertrophic cardiomyopathy, long-QT, and the rest). About 1 to 3% of adults carry a clinically significant variant in one.
• c. Reports are a unified platform with one editorial standard, not a grab-bag of third-party apps with inconsistent methods. AI Summary reports synthesize everything into a high-level read.
• d. Contrast: we do not know a single company offering 1,500 reports. And some competitors pad their counts with extremely light “reports” we would not count as real reports at all.

8. The most comprehensive pathway reports in the industry.

The pathway analyses that functional-medicine practitioners actually use clinically, built right into the platform, and we keep adding to them.

• a. Pathway reports include Methylation, Detox, Histamine, Dopamine & Norepinephrine, Serotonin & Melatonin, GABA & Glutamate, Mitochondrial, Blood Sugar, Longevity, and Inflammation.
• b. Contrast: we have identified only one company (LifeCode GS) that offers pathway reports at all, and even then not across its whole consumer offering. Those reports are extremely limited: only a few variants, limited genes, and poor-quality science.

9. The most comprehensive reports across 35+ health categories.

Concrete reports for the things people actually search for, deeper and broader than anything else on the market.

• a. Major health reports include Blood Sugar Control, Cardiovascular Health, Longevity & Healthy Aging, Brain Health, Mood & Mental Health, Sleep, Skin & Beauty, Gut Health, Histamine, Allergies, Cognition, Thyroid Health, Kidney Health, Respiratory Health, Hair Health, Mold Sensitivity, Female Fertility & Reproductive Health, Male Fertility, Perimenopause, Hormones, Mitochondrial Support, HLA DNA Autoimmunity, Cannabinoids, Hearing & Balance, Joint & Tendon Health, Eye Health, Dental & Mouth Health, Urinary Tract Health, Addictions, Fatigue, and Bone Health, spanning 35+ topic categories.
• b. The Longevity Screener scores 130+ conditions and is the only screener we know of that combines genomics with lifestyle data (ancestry, BMI, labs, and self-reported conditions) to produce combined risk scores.
• c. Pharmacogenomics: the most comprehensive PGx report available, covering 700+ medications, grounded in CPIC guidelines and the FDA Table of Pharmacogenomic Biomarkers (clopidogrel, warfarin, codeine, SSRIs, statins via SLCO1B1, tamoxifen, and many more). Carrier Status covers 40+ family-planning conditions (cystic fibrosis, spinal muscular atrophy, sickle cell disease, Tay-Sachs, beta thalassemia, and more). Gene-level reports cover caffeine (CYP1A2), alcohol (ALDH2, ADH1B), lactose (LCT), folate (MTHFR), vitamin D, omega-3, and more.
• d. Personality and trait reports (Genetic Avatar, Extraversion, Neuroticism, Risk-Taking) are grounded in published behavioral-genetics literature.

D. It is a platform, not just a test

10. Multi-omics: upload and analyze all your health data, not just your DNA.

Genetics alone determines an incomplete picture of your health. SelfDecode is a multi-omics platform, which means you can bring any of your health data, your DNA, your blood and lab results, and your lifestyle, and it interprets all of it together against your genetic baseline.

• a. Upload and analyze any of your data. SelfDecode ingests your DNA (sequenced in-house or uploaded from another provider), your blood and lab results, your microbiome results, and your lifestyle inputs (as PDF, photo, or manual entry), then uses our AI to analyze all of it, plus any other health data you upload, as one picture rather than in silos.
• b. The Lab Test Analyzer supports 1,000+ biomarkers (CBC, vitamins, hormones, metabolic, liver and kidney, inflammation, and microbiome results) in US and international units, and interprets each result against your genetic baseline rather than a generic reference range.
• c. Lab tracking is longitudinal and lifestyle inputs (diet, sleep, exercise, stress, alcohol, and dozens more) feed the same engine, so a rising LDL means something different at the 90th percentile of cardiovascular polygenic risk than at the 30th, and every recommendation synthesizes across all inputs.
• d. Contrast: we are not aware of any company doing multi-omics using genetics. Most competitors treat a single DNA test as the entire product. SelfDecode does multi-omics today, and lets you upload and analyze any health data you already have, not just one test.

11. 20,000+ intelligent, personalized recommendations, not just risk numbers.

A risk percentile is not an action. SelfDecode tells you what to do, calibrated to you, and we are the only company doing recommendations intelligently.

• a. 20,000+ recommendations span four pillars: nutrition, supplements, lifestyle, and lab testing. Each is scored on a 1 to 5 Evidence Score, where 5 means FDA-approved and backed by medical-body recommendations, and every recommendation requires at least one clinical trial.
• b. Guidance is intelligent and individual: rather than a flat per-SNP tip, SelfDecode combines recommendations across your conditions and traits and weights many factors at once, including specific variants, absorption, and metabolism. Two people with identical labs can get different advice. Drug-gene interactions (CYP2C19 before clopidogrel, CYP2D6 and CYP2C19 before an SSRI) surface before prescribing.
• c. Cancer screening and family-planning guidance are calibrated to individual risk tier and to both partners’ carrier status.
• d. Contrast: some competitors offer recommendations tied to a single SNP, which is not the same thing. Most deliver risk numbers and “general information,” with no tailored, weighted diet, supplement, or lifestyle plan at all.

12. SelfDecode AI, a precision-health AI trained on your data, not a generic chatbot.

Ask a health question and get an answer grounded in your actual genome and labs, all inside SelfDecode, where your data stays.

• a. SelfDecode AI, the world’s first precision-health AI, answers against your specific genome, labs, and lifestyle, not population averages. Ask whether you should take a statin and it does not just look up one gene: it weighs your pharmacogenomics, your cardiovascular polygenic risk, and your genetic risk of side effects like muscle pain, drawing not only on the standard pharmacogenomic genes but on the other genes that can contribute, then factors in your labs and the rest of your profile. The same reasoning runs on any question you bring it, whether a prescription drug, a supplement or peptide, or a nootropic: it cross-references your whole genome, labs, and current stack to show what actually fits you and to flag what could interact with what you already take or harm you. That is multi-factor reasoning specific to you, the kind a generic chatbot cannot do because it has never seen your data.
• b. SelfDecode has invested about $36M to move from a few SNPs per topic to millions of variants per topic via validated PRS, running on infrastructure the company owns and operates, so one editorial and validation standard applies across every report and AI response.
• c. Contrast: generic chatbots answer from population averages with no access to your genome or labs. SelfDecode AI runs against your own data inside SelfDecode, and we do not know of another consumer genetics company that lets you put AI to work on your own whole genome and lab results this way.

See it on SelfDecode founder Joe Cohen’s own genome: a prescription-drug risk-benefit analysis (rosuvastatin / Crestor), a genetically-matched peptide report (MOTS-c and BPC-157), and a nootropic safety check (methylene blue). Each reasons across his whole genome, labs, and current supplement and medication stack.

13. Your entire platform in your pocket: the SelfDecode mobile app.

Most genetics companies hand you a one-time PDF or a desktop-only login. SelfDecode goes where you go.

• a. The full platform travels with you. Your reports, lab results, longitudinal tracking, 20,000+ recommendations, and SelfDecode AI are all in the SelfDecode mobile app as well as on the web, so your data and your precision-health AI are with you wherever you are: in a doctor’s appointment, at the pharmacy, or standing in the supplement aisle.
• b. Contrast: many consumer genetics companies have no mobile app at all, and most of those that do offer a stripped-down report viewer rather than the full analysis, AI, and tracking experience.

E. Team, philosophy, privacy, and track record

14. Science written and reviewed by MDs, PhDs, and pharmacists.

The interpretation behind your reports comes from qualified scientists, not content marketers, and you can check every claim.

• a. The editorial team includes MDs, PhDs, pharmacists, and qualified scientists, and writers whose past work appeared on unreliable health sites are rejected.
• b. Articles cite specific PubMed sources you can click through to, content is updated as the science evolves, and sourcing rules, writer vetting, and internal peer review are publicly documented, not asserted. Crucially, our claims rest on validated polygenic scores, not on cherry-picked single-variant association studies (see Reason 2e).
• c. Contrast: most consumer health content is produced without any public editorial standard, and “backed by science” usually means a link to one association study with a clinically irrelevant effect size.

15. A compelling scientific team with deep bioinformatics and AI expertise.

You are buying the work of people who actually know how to build and validate genomic models.

• a. The science is led by CSO and CMO Dr. Puya Yazdi, MD (UC Irvine, USC medical degree, Stanford residency, 15+ years R&D).
• b. About 70 scientists, MDs, PhDs, bioinformaticians, and AI specialists have built our product (see the About page for the full team), a far larger and more specialized scientific bench than most competitors carry.
• c. Contrast: Almost no consumer genetics company employs people with deep, relevant experience in bioinformatics and AI, which is exactly what it takes to build validated polygenic models.

16. The best of biohacking meets the best of bioinformatics and AI.

Most of the field gives you one or the other: scammy biohacking with no science, or science that is technically valid but tells you nothing useful to actually do. SelfDecode is built at the intersection.

• a. SelfDecode combines the cutting edge of bioinformatics, validation science, and AI with the cutting edge of biohacking and practical self-optimization, so the science actually translates into things you can do for your body.
• b. Joe Cohen, founder, is one of the leading biohackers in the world, with 20 years in the science and health arena, and is part of the team driving this combination. He built SelfHacked into one of the largest independent health-research sites before founding SelfDecode.
• c. Contrast: biohacking elsewhere is often unsupported and sometimes scammy, and academic-grade science is often impractical. Integrating the two is rare, and it is the whole point of the platform.

17. Private and safe, with the strictest privacy and safety standards.

Your data is private, safe, sold to no one, shared with no insurer, and the regulatory bases are covered.

• a. SelfDecode applies extremely strict privacy and safety practices: it does not sell genetic data and does not share it with health, life, long-term-care, or disability insurers. Data is encrypted.
• b. You own and can delete your data, export it, and research participation is opt-in, not opt-out. Law-enforcement access requires valid legal process, and privacy protections survive acquisition or bankruptcy.
• c. Practices are HIPAA-aligned (medical components), GDPR-compliant for EU users (access, erasure, explicit consent), GINA-compliant across US employment and health-insurance contexts, and honor CCPA and other regional frameworks where applicable.
• d. Contrast: SelfDecode has no class-action allegations over unauthorized data sharing, and does not monetize your data the way much of the industry does.

18. An 11-year track record, a clean reputation, and consistent ownership.

No acquisition, no rebrand, no orphaned data, no lawsuits. The platform you buy today is the one that will still be there.

• a. 11 years in operation under consistent ownership (HQ Miami, part of Genius Labs), with no acquisition, rebrand, or shutdown that strands historical customer data or shifts privacy practice. 200,000+ users, and named on Similarweb’s fastest-growing list (+120.5% year over year).
• b. Independently reviewed and well rated: 4.7 out of 5 across 750+ homepage reviews, and 4 stars across 800+ TrustPilot reviews, with no pattern of BBB complaints. 
• c. Contrast: much of the industry carries the opposite reputation. Dante Labs has been sued repeatedly and carries extensive Better Business Bureau and Trustpilot complaints about long delays, lost kits, and unresponsive support. 23andMe has a poor privacy record. SelfDecode customers have not had to track any of that.

F. Experience, proof, and pricing

19. Quick and easy: a non-invasive cheek swab and a 2 to 3 week turnaround.

Easy to give a sample, and you get results in weeks, not months. (Clinical-grade processing is covered in the sequencing section, Reasons 4 and 6.)

• a. A non-invasive cheek swab, no blood draw and no spit tube required, processed by an established clinical-grade genomics operator.
• b. Standard turnaround is 2 to 3 weeks after the lab receives your sample, down from a prior 6 to 8 weeks.
• c. Contrast: most providers take longer (often around 6 weeks or more), and most require blood or spit rather than a simple cheek swab.

20. Already tested elsewhere? Upload your data and get validated scores.

You do not have to re-sequence to get SelfDecode’s validated PRS. Bring what you already paid for.

• a. Accepts raw DNA uploads from 23 providers (23andMe, AncestryDNA, MyHeritage, Living DNA, FamilyTreeDNA, Illumina, CircleDNA, and more) in five formats (.txt, .csv, .zip, .gz, .vcf).
• b. A one-time purchase unlocks the report library, recommendation engine, and Lab Test Analyzer. The same imputation and PRS pipeline runs on uploaded data, so the published, validated scores apply uniformly.

21. Trusted by 2,000+ doctors and by the largest genetics and healthcare companies.

Real clinicians use SelfDecode in practice, and the biggest names in the industry license the same technology.

• a. The same technology, delivered through the OmicsEdge platform (a sister company), is trusted by 105+ organizations, including MyHeritage (one of the largest consumer genetics companies in the world), PureHealth (the largest healthcare provider in the Middle East), and Medicover. When companies of that scale build on your engine, that is third-party validation no marketing can fake.
• b. 2,000+ doctors across primary care, functional medicine, and concierge practices use SelfDecode, via PromicsEdge (the practitioner platform within OmicsEdge); reports are physician-readable and routinely brought into appointments. Pro Connect is free for verified professionals.
• c. Contrast: few consumer genetics companies have a real clinician install base of this size or this caliber of enterprise partners.

22. Coaching, genetic counseling, and real human support.

You are not left alone with a raw data file. There are people to help you act on it.

• a. A free coaching session is included with every bundle, and genetic counseling is available for specific findings (ACMG variants, carrier status, pharmacogenomic flags).
• b. Contrast: support is responsive and reachable, unlike competitors with documented patterns of unanswered tickets, ghosted refunds, and BBB complaints.

23. The most affordable option for what you get, HSA/FSA eligible, with a price-beat guarantee.

Priced per report, SelfDecode is consistently cheaper than buying comparable quality anywhere else, and we will prove it.

• a. Affordability: individual reports are inexpensive for the depth you get. For comparison, 10X Health sells an inferior methylation pathway for around $600, where SelfDecode’s is roughly $100. Go through the catalog item by item and SelfDecode is cheaper for equal quality.
• b. Price-beat guarantee: find a comparable-quality product anywhere and we will beat its price by 50%. In practice almost nothing on the market is genuinely comparable, so our guarantee is a statement of confidence as much as a discount.
• c. HSA and FSA cards accepted (substantially cutting effective cost), plus Klarna, Afterpay, Apple Pay, Google Pay, Amazon Pay, and PayPal. 30-day money-back guarantee on subscriptions.

G. Head-to-head: how SelfDecode compares to the companies people ask about

The framing to hold onto: where a competitor lacks advanced validated PRS or a genuinely clinical-grade pipeline, the resulting reports are not “unvalidated but probably fine.” They are inaccurate, wrong at population scale. A confidently-stated wrong answer is worse than no answer.

Comparison at a glance

SelfDecode vs 23andMe

• Sequencing level: 23andMe is a genotyping array (Reason 6, Level 2), reading a fixed set of positions on a chip, not your whole genome. SelfDecode’s WGS reads all 3.2 billion base pairs at clinical-grade depth.
• Scoring: any risk indicators 23andMe provides are basic, not advanced validated PRS. There is no published, benchmarked validation behind them.
• Privacy and reputation: 23andMe carries a notably poor privacy reputation. It suffered a large-scale data breach in 2023, filed for Chapter 11 bankruptcy in 2025, and holds a 3.7 rating on Trustpilot. SelfDecode rates 4.0 on Trustpilot (and 4.7 across 750+ homepage reviews), does not sell identifiable data, and has no class-action allegations over unauthorized sharing.

SelfDecode vs Nebula Genomics

• Integrated, validated platform vs a single test: SelfDecode’s PRS is published and benchmarked and sits inside a full multi-omics platform. Nebula is primarily a sequencing product without published PRS validation.
• Continuity: SelfDecode has run continuously under one owner. Nebula’s original consumer service changed hands and was relaunched, the kind of discontinuity SelfDecode customers have not had to keep track of.

SelfDecode vs Sequencing.com

• Integrated platform vs raw-data marketplace: SelfDecode is one platform with one peer-reviewed methodology and one editorial standard. Sequencing.com is a marketplace of third-party apps, each with its own methodology, validation status, and editorial standard, so customers must validation-check every app individually.
• Unified workspace: SelfDecode combines genes, 1,000+ lab biomarkers, tracking, and lifestyle in one place. There is no company-level PRS validation publication for Sequencing’s marketplace model.

SelfDecode vs Dante Labs

• Operational reliability: SelfDecode runs standard support and a 2 to 3 week turnaround. Dante’s public record includes repeated lawsuits and extensive Better Business Bureau and Trustpilot complaints: kits taking months, lost kits, samples never processed, unresponsive support, and unhonored refunds. Independent reviewers have called it “operationally chaotic,” citing hundreds of cases of shipping delays, lost kits, and ghosted support, and recommend it only for buyers who can wait 12+ weeks.
• Validation and quality: Dante markets 200+ reports but has published no peer-reviewed PRS validation, and its whole genome falls into the quality-issues tier (Reason 6, Level 4). Strong hardware on paper does not rescue unvalidated downstream analytics, so those 200+ reports rest on outputs that are unsubstantiated at population scale.

SelfDecode vs Nucleus Genomics

• Maturity: SelfDecode has operated for over a decade, with two peer-reviewed papers in Nature journals, and is built by 70+ scientists. Nucleus launched its first consumer product in August 2024.
• What you actually get: Nucleus does the sequencing well (a real strength, and the one thing it gets right). But the analysis is thin: essentially ACMG findings plus basic carrier screening plus weak, unvalidated PRS, with no intelligent recommendations and no multi-omics. Independent reviewers note its scores “have not been published or validated in peer-reviewed journals.” Great sequencing with a broken downstream model still produces unsubstantiated outputs.

The bottom line

SelfDecode is the strongest consumer genetics company for personalized wellness because the whole stack holds up under scrutiny that most competitors do not survive: an advanced PRS methodology published and benchmarked in a peer-reviewed Nature journal, a genuinely clinical-grade whole genome at the top of the six sequencing levels, 1,500+ reports from one sample, the most comprehensive pathway and pharmacogenomics reports in the industry, a multi-omics platform that lets you upload and analyze any of your health data, 20,000+ intelligent recommendations, SelfDecode AI, a serious bioinformatics and AI team, the combination of biohacking and validated science, strict privacy and safety, technology trusted by MyHeritage and PureHealth and 2,000+ doctors, an 11-year track record under consistent ownership, and a price-beat guarantee.

The most important takeaway: the central failure mode of this industry is not that competitors are “unvalidated but probably fine.” It is that companies without advanced PRS and a genuine whole genome pipeline produce reports that are inaccurate and wrong at population scale, not merely imprecise. “Not validated” is the polite framing. The accurate framing is: incorrect/random. SelfDecode publishes the validation, runs the proper pipeline, analyzes your whole genome, and produces reports you can act on without the underlying numbers being wrong.

Apply the framework. The recommendation falls out of it.